Interruptions thérapeutiques: Pour ou contre?

Size: px

Start display at page:

Download "Interruptions thérapeutiques: Pour ou contre?"

Domenic Horton
5 years ago
Views:

1 Interruptions thérapeutiques: Pour ou contre? Lausanne, 19 avril 2007 Bernard Hirschel, Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland.

2 The Giant (SMART) And The 7 Dwarfs: Trivacan, Dart, Staccato, Windows, ISS, Basta, Salto

3 STI Update Overview A Detailed Look at SMART Confirmation: Trivacan and DART Opposition: Staccato and Windows Reconciliation Is there a way to make STIs «safe»? The cost-effectiveness of continuous therapy

4 SMART (Strategies for Management of anti-retroviral therapies) Patients with > 350 CD4 cells, mostly on treatment, willing to be randomized to 1. Drug conservation (DC or STI) arm: Treatment stopped if CD4 > 350, started at < Virologic suppression (VS or CT) arm: Keep VL < 50 at all times

5 SMART: As Planned NIH, CPCRA 6000 patients, planned follow-up of 5 to 9 years 900 endpoints expected in 2009, with power to detect difference of approximately 20% between arms

6 SMART: As It Turned out Recruitment suspended on January 11, 2006, after 5472 patients had been recruited, and 164 endpoints observed Excess of endpoints in the STI (DC) arm

7 Primary endpoint of OI/death STI group CT group Curves diverge after 4 months

8 SMART: Confirmed Events Event STI CT RR P N /100py N /100 py AIDS/death <10-4 Death

9 SMART: Type of AIDS Events Event STI CT Esophageal candidiasis 24 7 PCP 8 2 Recurrent bacterial pneumonia 7 2 Kaposi s 6 1 Persistent herpes simplex 3 2 Lymphoma 4 1 Disseminated zoster 3 1 TB 2 2 All others 7 2 Patients with any event 54 17

10 Few Deaths are AIDS-Related Type STI CT Cancer (excluding AIDS-related) 11 5 Cardiovascular 7 4 Substance abuse 3 5 Accident, suicide, violence 3 4 AIDS-related opp. disease 4 3 Other infections 3 1 Various other causes 9 5 Unknown 15 3 Total 55 30

11 SMART: (Supposedly) Drug-Related AEs Are Also Worse in STI Group Event STI CT RR P N /100py N /100 py MI, major CAD, stroke, RF, LF

12 Start of HAART

13 Years later, starting SMART SMART: Let s see whether we can save fuel by letting them swim a while. We can always pick them up downstream.

14 January 11, 2006 I don t want to wait until 2009!

15 STI Update Overview A Detailed Look at SMART Confirmation: Trivacan and DART Opposition: Staccato and Windows Reconciliation Is there a way to make STIs «safe»? The cost-effectiveness of continuous therapy

16 «Trivacan» Ivory Coast, 840 patients, ARV-naïves, CD4 count Treated > 6 mos until VL < 300, CD4 > CT 2. 2 months off / 4 months on 3. CD4-guided STIs: Stop if CD4 > 350, start if CD4 < 250

17 Trivacan: probability of remaining free from serious mobidity. Lancet 2006; 367:

18 Trivacan: Premature stop of the CD4-guided STIs Incidence per 100 years of follow-up Event CD4- CT arm p STI arm Bacteremia < Oral candida TB NS

19 «DART» Uganda/Zimbabwe Treated with ZDV/3-TC plus either NVP, TFV or ABC until CD4 > patients randomized, median CD CT weeks on / 12 weeks off

20 DART: Premature Stop of the STI Arm Incidence per 100 years of follow-up Event 12 wowo CT arm p STI arm AIDS (WHO stage 4) ART change for toxicity

21 DART: Premature Stop of the STI Arm Number of cases Event 12 wowo CT arm STI arm Esophageal candidiasis 17 4 Extrapulmonary TB 4 2 Cryptococcosis 2 2 Herpes simplex 2 1

22 STI Update Overview A Detailed Look at SMART Confirmation: Trivacan and DART Opposition: Staccato and Windows Reconciliation Is there a way to make STIs «safe»? The cost-effectiveness of continuous therapy

23 Staccato (Lancet 2006; 368:459) Swiss (19%) Thai (80%) Australia (1%) 430 patients, 24 mos Randomized 2:1 1. CD4 guided: ART to stop if CD4 > Continuous therapy Re-treatment for weeks in all at end

24 Staccato: Clinical events 1 death in each arm No AIDS-defining events Excess of candida stomatitis/vaginitis in STI arm (4% versus 1%) Approximately 60% drug savings No problems with resistance during and after re-treatment

25 Median length of STIs: 18 weeks 1.00 Probability to re-start ART Probability to re-start: 50% at 18 weeks 75% at 90 weeks Time from randomization (in weeks)

26 Staccato: Conclusions In pts treated mostly with boosted PI-based HAART: No excess in AIDS-defining OIs/deaths Little or no resistance Substantial drug savings Less adverse events ascribed to drugs May depend on type of regimen used

27 ANRS 106, "Windows" France, 403 patients Fully suppressed, CD4 > 450 (median 741), nadir > 100 (median 281) 1. Continuous therapy 2. 8 wks off / 8 weeks on for 96 weeks

28 Windows: Results at week 96 2 deaths (cirrhosis and violence) in STI group Excess of candida stomatitis (10 in STI vs 6 in CT), and thrombocytopenia (11 cases, all in patients who interrupted treatment) Marchou B et al., CROI 2006

29 Windows: Results at week 96 Primary Endpoint STI group CT group p CD4 < % 1.5% NS CD4 < % 8% 0.02 Little resistance was observed Marchou B et al., CROI 2006

30 Windows: Conclusions A fixed STI strategy of 8-wk-off/8-wk-on appeared clinically and immunologically safe over 96 weeks. Marchou B et al., CROI 2006

31 SMART Trivacan DART N of pts PY FU (in STI arm) CD4 at Stop median (min) 598 (350) 460 (350) 358 (300) CD4 at Start wowo AIDS, death/100py STI CT Time on ARV before study (mo)

32 SMART Windows Staccato N of pts PY FU (in STI arm) CD4 at Stop median (min) 598 (350) (350) CD4 at Start Median age (years) AIDS, death/100py STI CT Oral and vaginal candidiasis STI? CT? Mos on ARV before study Length of STIs (median, in months)

33 Are the Different Results due to the Differences in Size? None of the trials other than SMART were powered to detect differences in AIDS/death Were the trials too small and therefore succumbed to a type beta error (concluding that there is no difference whereas in fact there is)

34 Comparison of Staccato and SMART (2) Is the difference between Staccato and SMART «real»? - In SMART s DC (STI) arm, the incidence of disease progression was 3.5/100 PY - In Staccato s STI arm, 490 years of experience accumulated. At a rate of 3.5/100 PY, this would have produced 17 events, but only 1 was observed - The difference between 17 and 1 is unlikely to be due to chance (p < 0.001)

35 STI Update Overview A Detailed Look at SMART Confirmation: Trivacan and DART Opposition: Staccato and Windows Reconciliation Is there a way to make STIs «safe»? The cost-effectiveness of continuous therapy

36 SMART is large enough to permit meaningful analyses of subsets In almost all subgroups CT is favored Favors STI Favors CT

37 Duration of HAART Before Study Favors STI Favors CT Hazard Ratio

38 Nadir of CD4 Cells before Trial Favors STI Favors CT Hazard Ratio

39 Baseline CD4 Cells Favors STI Favors CT Hazard Ratio

40 Latest CD4 Cells During Trial STI patients with OD/death Min Median Max 25th 75th

41 Medians: 341 (STI), 515 (CT) STI Group CT Group Pts with OD/death All patients Pts with OD/death All patients

42 If none of the patients had had CD4 counts lower than 350, approximately half of AIDS/deaths in the STI group, but only a quarter of AIDS/deaths in the CT group, would have been eliminated. STI Group CT Group STI pts with OD/death CT pts with OD/death

43 What if Treatment Was Re-started at Higher CD4 Counts? STI* CT* RR Delta NNP CD4 strata < > * Number of patients with endpoints (AIDS or death) per 100 patientyears of follow-up. **NNP = number of patient years of treatment needed to prevent 1 event, considering that patients in the STI group were treated during 33 percent of days, compared to 94 percent in the CT group

44 The Cost-Effectiveness of HAART Numbers from Switzerland: - Before HAART, approx. 800 AIDS/Deaths per year - After HAART, approximately Approximately 5000 patients are being treated /700 or approximately 7 years worth of treatment to prevent one event

45 I would like to stop. Can I do so safely?

46 STI* CT* RR Delta NNP Last CD4 < > The Future of STIs (1): At higher CD4 counts: 500 to stop, 400 to start again

47 The Future of STIs (2): Limited in time to 4-6 months Caveats: although the curves looks suggestive, the hypothesis of no excess risk in short STIs has not been formally tested Further follow-up of SMART, to extend for 18 months, will determine how quickly the risk of re-treated patients in the STI group returns to the risk of the CT group

48 Further Research SMART suggests that events occur at appreciable frequency even though CD4 count is high a trial of earlier start of ARV Comparison of the trials suggests that disease rates are higher in Africa maybe CD4 levels that are safe in Europe are dangerous in Africa

49 Thank you! The Staccato Study - HIVNAT, Jintanat Ananworanich, Michelle LeBraz Swiss HIV Cohort Study Swiss National Science Foundation SMART State of Geneva Private donors Corporate sponsors, particularly Roche - James Neaton, Waffa El-Sadr and Jens Lundgren

50 The End

51 I feel like shit but I'm so happy that I don't have to take those pills anymore!

13 th Conference on Retroviruses and Opportunistic Infections (CROI)

REPORT FROM 13 th Conference on Retroviruses and Opportunistic Infections (CROI) February 5 8, 5 2006 Denver, CO 1 Tipranavir Significantly Reduces Concentrations of Other ARVs -10 % change PK -30-50 -70-68